PHAR
Pharming Group N.V.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
12.08
▲ 0.40 (3.42%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
11.76
Prev close
11.68
Day high
11.97
Day low
11.73
Volume
10.88K
Market cap
$838.72M
P/E (TTM)
84.64
52W range
9.62 – 21.34
Day trading desk
Gap from prior close
+0.68%
Prior close 11.68
VWAP
11.90
+1.47% from price
Relative volume
0.80×
Normal
Session range
2.98%
11.73 – 12.08
Position in range
100%
Near session high
ATR (14D)
0.64
5.28% of price
Prior day high
12.03
PDH
Prior day low
11.68
PDL
Bid / ask spread
—
Quote not published
Session volume
10.30K
Avg 12.95K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.11%
+2.5%
1M
-10.02%
-13.8%
3M
-7.49%
-10.6%
6M
-27.57%
-38.6%
YTD
-32.94%
-45.2%
1Y
-3.03%
-23.0%
3Y
-2.07%
-76.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PHAR open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$838.72M
Enterprise value$793.73M
Revenue (TTM)$366.48M
Gross profit$317.08M
EBITDA$32.88M
Net income$9.30M
EPS (TTM)$0.14
Free cash flow$37.69M
Total cash$158.28M
Total debt$113.30M
Book value / share$3.82
Shares outstanding70.78M
Float69.66M
Short % of float0.03%
Dividend yield—
Beta (5Y)0.06
Valuation & profitability ratios
Trailing P/E84.64
Forward P/E38.60
PEG ratio—
Price / sales—
Price / book3.10
EV / revenue2.17
EV / EBITDA24.14
Gross margin86.52%
Operating margin1.46%
Profit margin2.54%
Return on equity3.65%
Return on assets3.47%
Debt / equity41.89
Current ratio3.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $376.13M | $297.20M | $245.32M | $205.62M | +26.6% |
| Operating revenue | $376.13M | $297.20M | $245.32M | $205.62M | +26.6% |
| Cost of revenue | $45.50M | $35.40M | $25.21M | $17.56M | +28.5% |
| Gross profit | $330.63M | $261.80M | $220.10M | $188.06M | +26.3% |
| Research & development | $100.37M | $83.15M | $68.91M | $52.53M | +20.7% |
| Selling, general & admin | $117.44M | $99.22M | $87.50M | $68.85M | +18.4% |
| Total operating expense | $309.75M | $265.47M | $242.39M | $178.20M | +16.7% |
| Operating income | $20.88M | -$3.67M | -$22.29M | $9.86M | +669.7% |
| Net interest income | -$8.74M | -$5.09M | -$2.44M | -$5.38M | -71.8% |
| Pre-tax income | $12.85M | -$8.49M | -$12.01M | $14.99M | +251.3% |
| Tax provision | $10.31M | $3.35M | -$1.46M | $1.31M | +207.9% |
| Net income | $2.85M | -$11.84M | -$10.55M | $13.67M | +124.1% |
| Net income to common | $2.85M | -$11.84M | -$10.55M | $13.67M | +124.1% |
| Basic EPS | 0.04 | -0.16 | -0.15 | 0.21 | +125.0% |
| Diluted EPS | 0.04 | -0.16 | -0.15 | 0.19 | +125.0% |
| EBIT | $23.57M | $245.00K | -$6.05M | $20.34M | +9,518.8% |
| EBITDA | $34.78M | $16.32M | $9.88M | $33.53M | +113.2% |
| Basic shares | 71.28M | 68.78M | 67.46M | 65.11M | +3.6% |
| Diluted shares | 71.28M | 68.78M | 67.46M | 71.97M | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $145.31M | $54.94M | $61.74M | $207.34M | +164.5% |
| Cash & short-term investments | $179.10M | $167.89M | $213.42M | $207.34M | +6.7% |
| Accounts receivable | $41.77M | $41.53M | $35.41M | $20.96M | +0.6% |
| Inventory | $64.90M | $55.72M | $56.76M | $42.33M | +16.5% |
| Total current assets | $299.47M | $278.44M | $316.34M | $277.50M | +7.6% |
| Property, plant & equipment | $23.97M | $24.13M | $33.47M | $39.15M | -0.7% |
| Goodwill & intangibles | $135.54M | $61.04M | $71.27M | $75.12M | +122.1% |
| Total assets | $499.96M | $399.99M | $462.85M | $425.80M | +25.0% |
| Total current liabilities | $115.79M | $73.80M | $77.97M | $59.70M | +56.9% |
| Current debt | $5.34M | $4.25M | $1.82M | $1.77M | +25.7% |
| Long-term debt | $92.72M | $78.15M | $136.60M | $131.62M | +18.6% |
| Total debt | $115.78M | $112.31M | $171.54M | $166.69M | +3.1% |
| Total liabilities | $222.86M | $178.92M | $244.07M | $221.16M | +24.6% |
| Retained earnings | -$272.98M | -$275.49M | -$265.26M | -$256.43M | +0.9% |
| Shareholder equity | $277.10M | $221.06M | $218.78M | $204.64M | +25.4% |
| Working capital | $183.68M | $204.64M | $238.37M | $217.80M | -10.2% |
| Net tangible assets | $141.56M | $160.02M | $147.51M | $129.52M | -11.5% |
| Shares issued | 701.68M | 680.31M | 671.07M | 656.35M | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $12.85M | -$8.49M | -$12.01M | $14.99M | +251.3% |
| Depreciation & amortisation | $11.22M | $16.07M | $15.93M | $13.19M | -30.2% |
| Stock-based compensation | $13.77M | $11.25M | $9.25M | $6.39M | +22.4% |
| Change in working capital | $10.38M | -$10.07M | -$16.96M | -$387.00K | +203.1% |
| Operating cash flow | $54.71M | -$1.79M | -$17.30M | $22.46M | +3,147.8% |
| Capital expenditure | -$755.00K | -$796.00K | -$1.46M | -$1.98M | +5.2% |
| Investing cash flow | $26.25M | $31.62M | -$129.39M | $5.32M | -17.0% |
| Dividends paid | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $1.50M | -$34.41M | -$1.04M | -$4.98M | +104.3% |
| Free cash flow | $53.95M | -$2.59M | -$18.77M | $20.48M | +2,182.3% |
| End cash position | $145.31M | $54.94M | $61.74M | $207.34M | +164.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $90.21M | $72.45M | $106.50M | $97.29M | $93.22M | — | +24.5% |
| Operating revenue | $90.21M | $72.45M | $106.50M | $97.29M | $93.22M | — | +24.5% |
| Cost of revenue | $14.54M | $6.64M | $21.10M | $7.07M | $8.97M | — | +118.9% |
| Gross profit | $75.67M | $65.80M | $85.40M | $90.22M | $84.25M | — | +15.0% |
| Research & development | $32.26M | $25.56M | $32.10M | $23.38M | $23.70M | — | +26.2% |
| Selling, general & admin | $43.52M | $45.53M | $51.30M | $51.08M | $51.55M | — | -4.4% |
| Total operating expense | $75.78M | $71.09M | $83.40M | $74.47M | $75.25M | — | +6.6% |
| Operating income | -$111.00K | -$5.29M | $2.00M | $15.75M | $9.00M | — | +97.9% |
| Net interest income | -$4.13M | $542.00K | -$1.40M | -$7.33M | $519.00K | — | -861.8% |
| Pre-tax income | $3.04M | -$4.75M | $4.80M | $12.76M | $7.08M | — | +163.9% |
| Tax provision | $1.40M | $459.00K | -$500.00K | $5.21M | $2.53M | — | +205.4% |
| Net income | $1.64M | -$5.21M | $5.30M | $7.55M | $4.69M | — | +131.4% |
| Net income to common | $1.64M | -$5.21M | $5.30M | $7.55M | $4.69M | — | +131.4% |
| Basic EPS | — | -0.07 | 0.08 | — | — | -0.22 | — |
| Diluted EPS | — | -0.07 | 0.07 | — | — | -0.22 | — |
| EBIT | $5.71M | -$2.06M | $6.20M | $20.70M | $7.08M | — | +377.7% |
| EBITDA | $8.75M | $1.06M | $9.41M | $23.43M | $9.79M | — | +727.3% |
| Basic shares | — | 74.47M | 66.25M | — | — | 66.90M | — |
| Diluted shares | — | 74.47M | 75.71M | — | — | 66.90M | — |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $158.28M | $52.38M | $145.31M | $132.37M | $92.09M | +202.2% |
| Cash & short-term investments | $158.28M | $170.18M | $179.10M | $166.17M | $126.01M | -7.0% |
| Accounts receivable | $56.98M | $60.03M | $41.77M | $43.61M | $53.33M | -5.1% |
| Inventory | $65.43M | $64.58M | $64.90M | $67.14M | $63.72M | +1.3% |
| Total current assets | $280.69M | $295.51M | $299.47M | $277.60M | $245.78M | -5.0% |
| Property, plant & equipment | $20.48M | $23.10M | $23.97M | $24.99M | $24.57M | -11.3% |
| Goodwill & intangibles | $128.08M | $130.99M | $135.54M | $134.93M | $135.90M | -2.2% |
| Total assets | $467.98M | $489.37M | $499.96M | $473.79M | $446.26M | -4.4% |
| Total current liabilities | $93.25M | $112.35M | $115.79M | $87.91M | $87.94M | -17.0% |
| Current debt | $5.47M | $5.38M | $5.34M | $5.21M | $5.11M | +1.7% |
| Long-term debt | $92.40M | $93.39M | $92.72M | $93.14M | $91.27M | -1.1% |
| Total debt | $113.30M | $116.20M | $115.78M | $130.92M | $128.33M | -2.5% |
| Total liabilities | $197.49M | $220.41M | $222.86M | $209.14M | $206.71M | -10.4% |
| Retained earnings | -$278.25M | -$281.45M | -$272.98M | -$276.88M | -$286.03M | +1.1% |
| Shareholder equity | $270.49M | $268.96M | $277.10M | $264.64M | $239.55M | +0.6% |
| Working capital | $187.44M | $183.16M | $183.68M | $189.69M | $157.83M | +2.3% |
| Net tangible assets | $142.41M | $137.97M | $141.56M | $129.72M | $103.65M | +3.2% |
| Shares issued | 707.78M | 706.25M | 701.68M | 696.69M | 685.15M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $3.04M | -$4.75M | $4.80M | $12.76M | $7.08M | +163.9% |
| Depreciation & amortisation | $3.04M | $3.12M | $3.21M | $2.73M | $2.70M | -2.5% |
| Stock-based compensation | $3.35M | $3.23M | $4.51M | $3.20M | $3.48M | +3.9% |
| Change in working capital | -$18.14M | $445.00K | -$685.00K | $11.04M | -$1.39M | -4,176.4% |
| Operating cash flow | -$9.66M | $1.95M | $10.71M | $32.03M | $11.74M | -594.8% |
| Capital expenditure | -$83.00K | -$238.00K | -$269.00K | -$70.00K | -$128.00K | +65.1% |
| Investing cash flow | -$83.00K | -$84.76M | -$45.00K | -$349.00K | $16.95M | +99.9% |
| Dividends paid | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | -$2.45M | -$9.22M | $1.04M | $9.93M | -$2.76M | +73.5% |
| Free cash flow | -$9.74M | $1.71M | $10.44M | $31.96M | $11.62M | -668.3% |
| End cash position | $158.28M | $52.38M | $145.31M | $132.37M | $92.09M | +202.2% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.06 | 0.00 | -96.8% |
| Mar 2026 | 0.00 | -0.07 | -7,100.0% |
| Dec 2025 | 0.01 | 0.07 | +460.0% |
| Sep 2025 | 0.00 | 0.01 | +122.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.20 | 1 | $104.07M | +7.0% |
| Next quarter | 0.27 | 1 | $115.47M | +8.4% |
| Current year | 0.46 | 1 | $382.80M | +1.8% |
| Next year | 0.31 | 3 | $424.86M | +11.0% |
Analyst targets & ownership
Mean target$34.35
High target$39.00
Low target$23.40
Implied upside184.35%
Analyst count4
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.14%
Institutions holding21
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.86
+1.89% from price
SMA 20
11.49
+3.12% from price
SMA 50
12.59
-5.88% from price
SMA 100
13.75
-12.15% from price
SMA 200
15.29
-22.51% from price
EMA 12
11.74
+2.86% from price
EMA 26
11.96
+1.02% from price
EMA 50
12.47
-3.15% from price
RSI (14)
48.5
Neutral
MACD (12,26,9)
-0.21
Hist 0.13
ATR (14)
0.64
5.38% of price
Realised vol 30D
60.1%
Annualised
Bollinger upper
13.21
20, 2σ
Bollinger lower
9.78
20, 2σ
50 / 200 cross
Death
12.59 vs 15.29
Trend bias
Below 200
-22.51%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.02
More volatile than market
Correlation to SPY
0.19
Largely independent
Realised vol 30D
60.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-53.6%
Peak to trough
Max drawdown 5Y
-57.3%
Peak to trough
ATR 14
0.64
5.38% of price
Beta (reported)
0.06
5Y monthly, from filing
Short interest
Shares short
19.18K
Prior 3.20K
Change vs prior
+499.0%
Shorts adding
% of float
0.03%
Normal
% of shares out
0.03%
Against total outstanding
Days to cover
2.2
Liquid
Float
69.66M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 3, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Apr 10, 26 | Canaccord Genuity | INITIATED | — | Buy |
| Mar 24, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 13, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 14, 25 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Mar 14, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 17, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 9, 24 | Jefferies | INITIATED | — | Buy |
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-07-30
Corporate Changes & Voting Matters
6-K · 2026-06-04
Corporate Changes & Voting Matters
6-K · 2026-05-28
Corporate Changes & Voting Matters
6-K · 2026-05-22
Corporate Changes & Voting Matters
6-K · 2026-05-07
Corporate Changes & Voting Matters
6-K · 2026-04-16
Periodic Financial Reports
20-F/A · 2026-04-13
Headlines
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
GlobeNewswire · 10d ago
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · 19d ago
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
Simply Wall St. · 21d ago
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
GuruFocus.com · 24d ago
Pharming Group Q2 Earnings Call Highlights
MarketBeat · 24d ago
Pharming Group's Q2 Earnings, Revenue Fall; 2026 Revenue Outlook Updated
MT Newswires · 24d ago
Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
GlobeNewswire · 24d ago
Earnings To Watch: Pharming Group (XAMS:PHARM) Q2 2026 -- GF Value Sees 36% Upside
GuruFocus.com · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.